Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inventiva S.A.

3.56
+0.20005.95%
Volume:30.01K
Turnover:103.62K
Market Cap:340.56M
PE:-1.12
High:3.61
Open:3.47
Low:3.26
Close:3.36
Loading ...

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

GlobeNewswire
·
16 Apr

Inventiva Is Maintained at Buy by Guggenheim

Dow Jones
·
04 Apr

Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?

Zacks
·
04 Apr

Inventiva price target lowered to $9 from $12 at Guggenheim

TIPRANKS
·
04 Apr

Inventiva Sa : Guggenheim Cuts Target Price to $9.00 From $12.00

THOMSON REUTERS
·
04 Apr

Inventiva Price Target Maintained With a $13.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Apr

Inventiva achieves milestone with Phase 3 study enrollment, says H.C. Wainwright

TIPRANKS
·
03 Apr

Inventiva Completes Enrollment in Phase 3 Study of Liver Treatment

MT Newswires Live
·
02 Apr

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

GlobeNewswire
·
02 Apr

Inventiva (IVA) Gets a Buy from Canaccord Genuity

TIPRANKS
·
01 Apr

Inventiva SA (IVEVF) (Q4 2024) Earnings Call Highlights: Navigating Financial Challenges and ...

GuruFocus.com
·
28 Mar

Inventiva FY24 EPS €(3.08) Down From €(2.43) YoY; Revenue €9.2 Million Down From €17.48 Million YoY

Benzinga
·
27 Mar

Inventiva reports its 2024 full year results and provides a business update

GlobeNewswire
·
27 Mar

Inventiva SA expected to post a loss of 52 cents a share - Earnings Preview

Reuters
·
24 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
24 Mar

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

GlobeNewswire
·
20 Mar

Optimistic Buy Rating for Inventiva Driven by Lanifibranor’s Promising Phase 3 Prospects and Safety Profile

TIPRANKS
·
21 Feb

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Organon (OGN) and Inventiva (IVA)

TIPRANKS
·
12 Feb

Inventiva Reports €9.2M 2024 Revenues, €96.6M Cash As Of December 31, 2024; €116M Tranche Of €348M Financing Secured; Last Patient Screened For NATiV3 Phase 3 Lanifibranor Trial; Workforce Cut By 50% To Focus On Lanifibranor Development

Benzinga
·
11 Feb

Inventiva Price Target Maintained With a $13.00/Share by HC Wainwright & Co.

Dow Jones
·
31 Jan